Nick began his career in 1982 as a Eurobond trader with SGST Securities, a subsidiary of Societe Generale, before joining a private bank, BSI, as a fund manager. After completing an MBA he worked as a consultant on a number of alternative investment projects and in 2003 joined hedge-fund manager Continuous Time Finance LLP as their COO. He has been the Fund Manager of AM2 (Bermuda) Limited since inception (2006) and co-manages the New Science Global Healthcare Fund. Nick is a holder of the Investment Management Certificate from the UK Society of Investment Professionals.
Dr. Wang Chong
Following a medical degree and MBA, Wang worked in the healthcare/lifesciences industry for 27 years and 13 years in the financial sector. He offers a unique combination of world class healthcare industry operational expertise and financial skills. When CEO and CFO of UK premium-listed biopharmaceutical and medical diagnostic companies, he achieved two FDA product approvals and two multinational out-licensing deals with Unilever plc and Schering Plough Inc. He is experienced in fundraising for and listing small to mid-cap companies, and been instrumental in raising over £60 million. Wang is President of the Royal Society of Medicine’s Pharmaceutical Medicine & Research Section.
Simon qualified as a Chartered Accountant in 1999, and has over 16 years of corporate finance experience with Evolution Securities, Daniel Stewart & Co, Fox-Davies Capital and BDO LLP. He has provided financial and regulatory advice to a number of private and public companies in retained and transaction roles. He has acted as lead corporate finance adviser on a broad range of transaction types, and in doing so fulfilled the role of Nominated Adviser for the LSE’s AIM market and sponsor for the LSE’s Main Market.